Close

JB Pharma to acquire the entire Razel (Rosuvastatin) franchise for Rs. 314 crores

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

AI in Genomics Market – Setting Pace for Vast Genomic Data

There is no shred of doubt that artificial intelligence...

Recyclable Pharma Packaging: Market To Hit $335B By 2032

There will be a lot more demand for recyclable...

Key Trends Shaping Indian Pharmaceutical Packaging Market

The pharmaceutical business has a major economic influence on...

JB Pharma, one of the fastest growing pharmaceutical companies in India, has entered into an agreement with Glenmark Pharmaceuticals Ltd., to acquire the entire Razel (Rosuvastatin) franchise for the India and Nepal region for a whopping Rs. 313.7 crores. With this acquisition, JB Pharma will complete its cardiac portfolio making it a leader in this segment, as Razel ranks among the top 10 brands in the Rosuvastatin molecule category in the country. These brands are focused on cardiac segment in India and Nepal with a total covered market size of INR 2,444 crores as per IQVIA MAT Oct’22 numbers.

Commenting on the acquisition, Mr. Nikhil Chopra, CEO and Whole Time Director, JB Pharma said, “We are glad to announce the acquisition of the Razel (Rosuvastatin & combinations) franchise, thereby marking JB’s expansion into Statins, which is the largest therapeutic segment in cardiology.  With this addition, we now have established strong position in statins besides being among the leaders in Hypertension and Heart failure – all the fastest growing therapeutic indications in cardiology.†He further added “We see good growth potential from the acquired brands. This acquisition will help us leverage our existing Go-To-Market model focussed for this segment and further strengthen our chronic portfolio.â€

Latest stories

Related stories

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

AI in Genomics Market – Setting Pace for Vast Genomic Data

There is no shred of doubt that artificial intelligence...

Recyclable Pharma Packaging: Market To Hit $335B By 2032

There will be a lot more demand for recyclable...

Key Trends Shaping Indian Pharmaceutical Packaging Market

The pharmaceutical business has a major economic influence on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back